These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Renews GMP certifications for India and Malaysia sites
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Both organisations enter into a long- term collaboration to expand patient access in India
This agreement paves the way for the introduction of YESAFILI into the Canadian market
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
10+ emerging markets, Japan & ANZ transition in final phase
Subscribe To Our Newsletter & Stay Updated
